Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Modified One Anastomosis Gastric Bypass (OAGB) Versus Duodenojejunostomy for Treatment of Superior Mesenteric Artery Syndrome: A Randomized Controlled Trial.

Created on 10 Jul 2026

Authors

Ahmed A A Y Salem, Mohey R Elbanna, Amr A M Abdel-Alim, Mohammed A Hamed

Published in

Surgical laparoscopy, endoscopy & percutaneous techniques. Jul 07, 2026. Epub Jul 07, 2026.

Abstract

Superior mesenteric artery syndrome is a rare cause of upper gastrointestinal obstruction. Surgical treatment is indicated when conservative measures fail; duodenojejunostomy is the most commonly performed procedure, although persistent or recurrent symptoms have been reported. We propose a modified one anastomosis gastric bypass (OAGB) as a functional reconstructive bypass to relieve duodenal obstruction.
This prospective randomized controlled trial included 20 patients with SMA syndrome, randomized equally to modified OAGB or duodenojejunostomy. Symptom severity and quality of life were assessed preoperatively and at 1, 3, 6, and 12 months.
Modified OAGB resulted in higher WHOQOL-BREF scores at 12 months (59.3±10.0 vs. 42.7±15.9, P=0.014), lower rates of recurrent vomiting (20% vs. 50%), and shorter hospital stay (4.1±0.32 d vs. 6.8±2.94 d, P=0.017).
Modified OAGB may represent a feasible and effective alternative to duodenojejunostomy for selected patients.

PMID:
42425962
Bibliographic data and abstract were imported from PubMed on 10 Jul 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 4
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement